Suppr超能文献

地尔硫䓬与美托洛尔在急诊科治疗快速心室率心房颤动或心房扑动中的对比

Diltiazem vs. Metoprolol in the Management of Atrial Fibrillation or Flutter with Rapid Ventricular Rate in the Emergency Department.

作者信息

Fromm Christian, Suau Salvador J, Cohen Victor, Likourezos Antonios, Jellinek-Cohen Samantha, Rose Jonathan, Marshall John

机构信息

Department of Emergency Medicine, Maimonides Medical Center, Brooklyn, New York.

Department of Emergency Medicine, Maimonides Medical Center, Brooklyn, New York; Arnold & Marie College of Pharmacy and Allied Health Sciences, Brooklyn, New York.

出版信息

J Emerg Med. 2015 Aug;49(2):175-82. doi: 10.1016/j.jemermed.2015.01.014. Epub 2015 Apr 22.

Abstract

BACKGROUND

Diltiazem (calcium channel blocker) and metoprolol (beta-blocker) are both commonly used to treat atrial fibrillation/flutter (AFF) in the emergency department (ED). However, there is considerable regional variability in emergency physician practice patterns and debate among physicians as to which agent is more effective. To date, only one small prospective, randomized trial has compared the effectiveness of diltiazem and metoprolol for rate control of AFF in the ED and concluded no difference in effectiveness between the two agents.

OBJECTIVE

Our aim was to compare the effectiveness of diltiazem with metoprolol for rate control of AFF in the ED.

METHODS

A convenience sample of adult patients presenting with rapid atrial fibrillation or flutter was randomly assigned to receive either diltiazem or metoprolol. The study team monitored each subject's systolic and diastolic blood pressures and heart rates for 30 min.

RESULTS

In the first 5 min, 50.0% of the diltiazem group and 10.7% of the metoprolol group reached the target heart rate (HR) of <100 beats per minute (bpm) (p < 0.005). By 30 min, 95.8% of the diltiazem group and 46.4% of the metoprolol group reached the target HR < 100 bpm (p < 0.0001). Mean decrease in HR for the diltiazem group was more rapid and substantial than that of the metoprolol group. From a safety perspective, there was no difference between the groups with respect to hypotension (systolic blood pressure < 90 mm Hg) and bradycardia (HR < 60 bpm).

CONCLUSIONS

Diltiazem was more effective in achieving rate control in ED patients with AFF and did so with no increased incidence of adverse effects.

摘要

背景

地尔硫䓬(钙通道阻滞剂)和美托洛尔(β受体阻滞剂)均常用于急诊科(ED)治疗心房颤动/扑动(AFF)。然而,急诊医生的实践模式存在相当大的地区差异,医生们对于哪种药物更有效也存在争议。迄今为止,仅有一项小型前瞻性随机试验比较了地尔硫䓬和美托洛尔在急诊科控制AFF心率方面的有效性,得出两种药物在有效性上无差异的结论。

目的

我们的目的是比较地尔硫䓬和美托洛尔在急诊科控制AFF心率方面的有效性。

方法

将出现快速心房颤动或扑动的成年患者便利样本随机分配接受地尔硫䓬或美托洛尔治疗。研究团队对每位受试者的收缩压、舒张压和心率进行30分钟监测。

结果

在前5分钟,地尔硫䓬组50.0%的患者以及美托洛尔组10.7%的患者达到了每分钟心率(HR)<100次(bpm)的目标心率(p<0.005)。到30分钟时,地尔硫䓬组95.8%的患者以及美托洛尔组46.4%的患者达到了目标心率<100 bpm(p<= 0.0001)。地尔硫䓬组心率的平均下降比美托洛尔组更快且更显著。从安全性角度来看,两组在低血压(收缩压<90 mmHg)和心动过缓(HR<60 bpm)方面无差异。

结论

地尔硫䓬在急诊科AFF患者中实现心率控制方面更有效,且未增加不良反应的发生率。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验